Creating a living tissue bank from glioma tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish patient-derived organoids from low-grade and high-grade gliomas to better understand the mechanisms behind tumor behavior and treatment resistance. By characterizing these organoids phenotypically, genetically, and transcriptomically, researchers hope to develop patient avatars that can be used to test various treatment modalities. The study will also explore the effects of different therapies, including immunotherapy and radiation, on these organoids. Ultimately, the goal is to improve treatment outcomes for glioma patients by identifying effective therapeutic strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
* Age 18 years or older
* Patient is eligible for a resection of the tumor

Exclusion Criteria:

* Contra-inidication for neurosurgical resection of the tumor.
* Incapacitated patient, unable to give informed consent.

Where it's running

• Maastricht Radiation Oncology
  Maastricht, Limburg, Netherlands Recruiting

Study contacts

• Principal investigator: Marc Vooijs, Prof. Dr. — Maastro Radiaton Oncology clinic
• Study coordinator: Annika Noordink, Msc
• Email: annika.noordink@maastro.nl
• Phone: +31(0)884456010

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining MAPK inhibitors with anti-PD1 therapy for pediatric gliomas with BRAF alterations

  This study is testing if combining two cancer drugs with a new therapy can help children with certain types of brain tumors feel better and have more treatment options.

  Recruiting Phase 1/2 Ann & Robert H Lurie Children's Hospital of Chicago · Washington D.C., District of Columbia and 2 other locations · NCT06712875

• Taste of hope: testing NRG-103 safety and dosing for adults with high-grade glioma

  This early-phase trial tests whether NRG-103 is safe and tolerable in adults with recurrent or progressive high-grade glioma and looks for early signs it might help.

  Recruiting at 2 sites Phase 1 Neuregen Therapeutics Co., Ltd. · Shanghai and 2 other locations · NCT07710690

• Low-grade gliomas in Argentina: Incidence, survival, and treatment patterns

  This study tests how common low-grade gliomas are in Argentina and how long patients live after diagnosis, using two groups from Buenos Aires and Córdoba.

  Recruiting at 6 sites Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires F.D. and 5 other locations · NCT07631338

• Laser thermal therapy for young people with low-grade glioma

  This research will test whether laser interstitial thermal therapy (LITT) can stop or slow recurrent or progressive low-grade gliomas in children, adolescents, and young adults.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07506239

• Dual-target CAR-NK cell therapy for recurrent glioblastoma and high-grade glioma

  This phase 1 study will test whether injecting dual-target CAR-NK cells into the brain is safe and can help adults with recurrent or progressive glioblastoma or other high-grade gliomas.

  Recruiting Phase 1 Beijing Biotech · Shenzhen, Guangdong · NCT07480941

• Intratumoral DNX-2401 for High-Grade Pediatric Brain Tumors

  This study tests whether a single injection of DNX-2401 into a pediatric brain tumor can help shrink the tumor and extend survival in kids and young adults with recurrent or refractory high-grade brain tumors.

  Recruiting Phase 2 Clinica Universidad de Navarra, Universidad de Navarra · Utrecht and 1 other locations · NCT07424092

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.